UROKINASE MEDAC 500000 IU Israel - English - Ministry of Health

urokinase medac 500000 iu

tzamal bio-pharma ltd - urokinase - powder for solution for injection - urokinase 500000 iu - urokinase - urokinase - peripheral arterial thrombosis ;acute and subacute deep vein thrombosis ; acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; thrombosed arteriovenous shunt.

BENDAMUSTINE MEDAC 100 MG Israel - English - Ministry of Health

bendamustine medac 100 mg

tzamal bio-pharma ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 100 mg - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

BENDAMUSTINE MEDAC 100 MG Israel - English - Ministry of Health

bendamustine medac 100 mg

tzamal bio-pharma ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 100 mg - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

BENDAMUSTINE MEDAC 25 MG Israel - English - Ministry of Health

bendamustine medac 25 mg

tzamal bio-pharma ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 25 mg - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

BENDAMUSTINE MEDAC 25 MG Israel - English - Ministry of Health

bendamustine medac 25 mg

tzamal bio-pharma ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 25 mg - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

Eposin, concentrate for solution for infusion 20mg/ml United Kingdom - English - myHealthbox

eposin, concentrate for solution for infusion 20mg/ml

pharmachemie b.v. - etoposide, ph.eur. - concentrate for solution for infusion (to dilute). - 20mg/ml - podophyllotoxine derivatives - for the management of: - testicular tumours in combination with other chemotherapeutic agents - small cell lung cancer, in combination with other chemotherapeutic agents - monoblastic leukaemia (aml m5) and acute myelomonoblastic leukaemia (aml m4) when standard therapy has failed (in combination with other chemotherapeutic agents).

DACARBAZINE MEDAC 1000 MG Israel - English - Ministry of Health

dacarbazine medac 1000 mg

tzamal bio-pharma ltd - dacarbazine as citrate - powder for solution for inj/inf - dacarbazine as citrate 1000 mg/vial - dacarbazine - decarbazine is indicated for the treatment of patients with metastatic malignant melanoma. further indications for dacarbazine as part of a combination chemotherapy in advanced hodgkin's disease as a second line.